"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Personalized Medicine Market size is worth USD 242.8 Billion in 2025 and is projected to reach USD 618.5 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 9.8% from 2026 to 2035. Key trends include increasing adoption of personalized therapeutics, expanding genomic sequencing, AI and machine learning driven clinical decision support, growing use of companion diagnostics, biomarker guided treatment selection, pharmacogenomic testing, interoperable genomic data platforms, and rising investment in integrated precision healthcare ecosystems.

United States Personalized Medicine Market Overview

The United States Personalized Medicine Market is witnessing strong growth as healthcare providers, pharmaceutical companies, diagnostic laboratories, and research institutions increasingly transition toward individualized treatment and diagnostic strategies. Personalized medicine integrates genomic information, molecular diagnostics, advanced therapeutics, digital health technologies, and clinical analytics to support patient specific treatment pathways and improve healthcare outcomes.

The increasing availability of genomic sequencing technologies is significantly driving market expansion. Declining sequencing costs, higher analytical throughput, and improved laboratory workflows are enabling broader clinical implementation of genomic testing across oncology, rare diseases, cardiovascular conditions, neurology, and other complex disease categories. Healthcare organizations are increasingly investing in scalable sequencing infrastructure, bioinformatics platforms, and interoperable data systems capable of integrating genomic insights into routine clinical decision making.

Pharmaceutical companies are also strengthening demand through the growing development of targeted therapeutics and biomarker guided clinical programs. Companion diagnostics are becoming increasingly important for identifying appropriate patient populations and supporting treatment selection, while pharmacogenomic testing is expanding as healthcare providers seek to understand individual variations in drug response and optimize medication strategies.

Artificial intelligence and machine learning are emerging as major technology trends across the United States precision healthcare ecosystem. AI enabled platforms can integrate genomic information, medical imaging, pathology findings, laboratory data, and electronic health records to support biomarker identification, patient stratification, predictive analytics, and clinical decision support. These capabilities are helping healthcare organizations improve diagnostic efficiency and strengthen personalized treatment planning.

Hospitals and integrated healthcare systems remain major commercial adopters because they possess the infrastructure required to combine diagnostic, laboratory, therapeutic, pharmacy, and clinical data within coordinated care environments. Diagnostic laboratories, specialty clinics, pharmaceutical companies, biotechnology organizations, and academic research institutions are also expanding their precision medicine capabilities.

Overall, the United States Personalized Medicine Market is expected to experience sustained long-term growth as healthcare organizations prioritize precision driven treatment, predictive diagnostics, operational efficiency, and interoperable digital healthcare infrastructure. The increasing integration of genomics, artificial intelligence, companion diagnostics, and targeted therapeutics is expected to further strengthen the strategic importance of personalized medicine across the United States healthcare system.

Guardant Health Announced Multi Year Collaboration with Merck to Advance Companion Diagnostic Development

January 2026 — Guardant Health announced a multi year collaboration with Merck to advance companion diagnostic development and commercialization using its precision oncology platform, strengthening the integration of biomarker intelligence with targeted treatment strategies.

Key Takeaways from the Report

Personalized Therapeutics represented nearly 39.4% of overall revenue, reflecting extensive adoption of individualized treatment strategies across complex disease categories.
Artificial Intelligence & Machine Learning technology is projected to register a CAGR of approximately 12.7%, supported by predictive analytics, clinical decision optimization, and automated interpretation of complex healthcare datasets.
Oncology contributed over 35.2% of application demand, driven by expanding adoption of biomarker guided treatment selection, genomic profiling, companion diagnostics, and targeted therapies.
Institutional procurement represented nearly 57.1% of commercial purchasing, highlighting the importance of enterprise healthcare investments and long term procurement agreements.
Genomic sequencing continues to expand across hospitals and diagnostic laboratories as declining technology costs and improved analytical capabilities support broader clinical adoption.
Pharmaceutical companies are increasingly integrating biomarker guided clinical trials and companion diagnostics into drug development and commercialization strategies.
Hospitals remain major end users as healthcare systems integrate genomic diagnostics, targeted therapeutics, laboratory services, and clinical decision support into coordinated precision healthcare programs.
AI enabled clinical analytics and bioinformatics platforms are creating new opportunities for automated genomic interpretation, predictive modeling, patient stratification, and personalized treatment planning.

Top Players

Illumina, Inc.
Thermo Fisher Scientific Inc.
Hoffmann La Roche Ltd.
Guardant Health, Inc.
Tempus AI
QIAGEN N.V.
Myriad Genetics, Inc.
Exact Sciences Corporation
Foundation Medicine, Inc.
Pfizer Inc.
AstraZeneca PLC
Danaher Corporation

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID 19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies. The analysis evaluates genomic sequencing, proteomics, metabolomics, transcriptomics, artificial intelligence, bioinformatics platforms, personalized therapeutics, personalized diagnostics, companion diagnostics, pharmacogenomic testing, hospital based precision medicine programs, clinical laboratories, specialty clinics, direct to consumer services, and institutional procurement models across the US healthcare ecosystem.

Latest Announcement

March 2026 — Tempus AI expanded its strategic collaboration with Merck to accelerate AI enabled biomarker discovery and precision drug development, reinforcing the role of artificial intelligence in pharmaceutical research and personalized healthcare commercialization.